Solta Medical, Inc.
), leader in medical devices for aesthetic treatment recently
announced an exclusive partnership with SkinCeuticals, a provider
of professional skincare technology, to provide first fractional
laser treatment as well as antioxidant skincare regimen for office
and home use.
The partnership will combine data from clinical research
undertaken by Solta and SkinCeuticals. The research analyzed the
merits of using Clear+Brilliant Laser System along with its
handpiece Permea, manufactured by Solta and SkinCeutical's
antioxidant named CE Ferulic.
The results from the clinical research indicate enhanced patient
satisfaction based on the appearance of the skin. Skin treatment
using Clear+Brilliant Permea followed by CE Ferulic resulted in a
reduced post-treatment recovery time. As per statistics, the
combination of CE Ferulic and Clear+Brilliant Laser System can
lower the recovery time by two days. The patients also experienced
less redness and swelling.
Management at Solta is enthused about its partnership with
SkinCeuticals. The company considers its Clear+Brilliant system to
be the preferred choice for physicians who want to offer maximum
benefits of a fractional resurfacing treatment to their patients.
The addition of the Permea handpiece and inclusion of CE Ferulic in
the treatment regimen will allow Solta to offer holistic treatment
to patients in the office as well as at home.
According to management at SkinCeuticals, laser treatment
offered by Solta complements its skincare technology. CE Ferulic
offers antioxidant treatment to negate the harmful free radicals
and enhance the skin's natural photoprotection eight times. It can
also curtail inflammation and activate collagen synthesis.
Solta is a developer and manufacturer of medical devices for
aesthetic application for physician-led, professional assists and
personal care market. The company operates in a burgeoning market,
given the demand outlook and demographic trend. Its partnership
with SkinCeuticals underlines Solta's commitment towards the
aesthetic medical industry. The company has a history of product
innovation and successful takeovers to boost its top-line.
However, the market that Solta serves is susceptible to
macroeconomic pressure. Moreover, the company faces tough
Syneron Medical Ltd.
Solta currently retains a Zacks #3 Rank, which translates into a
short-term Hold rating.
SYNERON MED LTD (ELOS): Free Stock Analysis
SOLTA MEDICAL (SLTM): Free Stock Analysis
To read this article on Zacks.com click here.